Clinical Trials Logo
  1. Home
  2. Autoimmune Diseases
  3. NCT06375993
  4. Details
NCT06375993 Clinical Trial

A Phase 1 Study of ADI-001 in Lupus Nephritis

Autoimmune Diseases Clinical Trial

Official title:
A Phase 1 Study of ADI-001 Anti-CD20 CAR-engineered Allogeneic Gamma-Delta (γδ) T Cells in Adults With Lupus Nephritis

Clinical Trial Details — Status: Not yet recruiting

Administrative data
NCT number NCT06375993
Other study ID # ADI-202300103
Secondary ID
Status Not yet recruiting
Phase Phase 1
First received
Last updated
Start date June 2024
Est. completion date December 2027

Study information
Verified date June 2024
Source Adicet Therapeutics
Contact Adicet Medical Director
Phone 650-503-9095
Email clinicaltrials@adicetbio.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

ADI-202300103 is a phase 1 multicenter, open label, dose finding and dose expansion safety/efficacy study in patients with lupus nephritis. The study will consist of different periods including screening, lymphodepletion, treatment, and follow-up

Recruitment information / eligibility
Status Not yet recruiting
Enrollment 40
Est. completion date December 2027
Est. primary completion date December 2026
Accepts healthy volunteers No
Gender All
Age group 18 Years to 80 Years
Eligibility Inclusion Criteria: 1. Clinical diagnosis of systemic lupus erythematosus (SLE) per 2019 European League Against Rheumatism (EULAR)/American College of Rheumatology (ACR) classification criteria (Aringer 2019). 2. Active kidney disease with biopsy-proven active LN Class III or IV (coexistent class V permitted) (per 2018 International Society of Nephrology [ISN]/Renal Pathology Society [RPS] criteria) ; biopsy should be performed within 6 months before enrolling in the study. 3. ECOG performance = 2 4. Proteinuria (or urine protein creatinine ratio [UPCR]) > 1g / 24 hours. Exclusion Criteria: 1. LN pure class V, per 2018 ISN/RPS criteria (Bajema 2018). 2. Presence of severe liver disease, Child-Pugh class B or C. 3. Presence of autoimmune diseases other than SLE as the main diagnosis 4. Current or history of severe central nervous system involvement. 5. Presence of kidney impairment due to etiologies other than LN . 6. Prior treatment with any gene therapy, genetically modified cell therapy, or adoptive T cell therapy.

Study Design

Related Conditions & MeSH terms

Intervention

Drug:
• ADI-001
Anti-CD20 CAR-T
• Fludarabine
Chemotherapy for Lymphodepletion
• Cyclophosphamide
Chemotherapy for Lymphodepletion

Locations
Country Name City State
n/a

Sponsors (1)
Lead Sponsor Collaborator
Adicet Therapeutics

Outcome
Type Measure Description Time frame Safety issue
Primary The Incidence of Subjects with Dose Limiting Toxicities within each dose level cohort This primary endpoint will be used to determine the Maximum Tolerated Dose (MTD) or Maximum Assessed dose (MAD) 28 Days
Primary Proportion of treatment emergent and treatment related adverse events This primary endpoint will be used to determine the MTD/MAD of ADI-001 2 year
See also
  Status Clinical Trial Phase
Recruiting NCT04078698 - Documentation of the Safety and Effectiveness Profile of the IgG Immunoadsorber GLOBAFFIN® in Clinical Routine N/A
Recruiting NCT04039763 - RT-CGM in Young Adults at Risk of DKA N/A
Recruiting NCT05670301 - Flemish Joint Effort for Biomarker pRofiling in Inflammatory Systemic Diseases N/A
Completed NCT03266172 - A Study to Compare the Pharmacokinetics (PK) of GSK2982772 Following Administration of Different Modified Release (MR) Formulations in Capsule and MR Tablet Formulations Relative to an Immediate Release (IR) Tablet Formulation and to Check the PK of MR Formulation in Capsule Following Repeat Doses Phase 1
Completed NCT03649412 - A Study to Investigate the Pharmacokinetics (PK) of Modified Release (MR) Prototype Coated Tablet Formulations of GSK2982772 Phase 1
Recruiting NCT04561557 - Safety and Efficacy of CT103A Cells for Relapsed/Refractory Antibody-associated Inflammatory Diseases of the Nervous System Early Phase 1
Completed NCT03173144 - Chronic Inflammatory Disease, Lifestyle and Treatment Response
Completed NCT00975936 - Phase 0 Microdose Study Phase 1
Not yet recruiting NCT05969821 - Clonal Hematopoiesis of Immunological Significance
Completed NCT01210716 - Evaluation of Therapeutic Plasma Exchange (TPE) Procedure Using the AMICUS Device Phase 3
Completed NCT00820469 - Study of the Influence of Plasma Exchange on the Pharmacokinetics of Rituximab Phase 4
Completed NCT01953523 - Safety and Clinical Outcomes Study: SVF Deployment for Orthopedic, Neurologic, Urologic, and Cardio-pulmonary Conditions N/A
Withdrawn NCT03239600 - A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), Proof of Mechanism of GSK2618960 in Primary Sjögren's Syndrome (pSS) Phase 2
Completed NCT04872257 - Oral Vitamin D Supplementation Combined With Phototherapy as a Treatment for Vitiligo N/A
Recruiting NCT06019611 - Epidural Stimulation in Multiple Sclerosis N/A
Recruiting NCT05030779 - A Study of CD19/BCMA Chimeric Antigen Receptor T Cells Therapy for Patients With Refractory Systemic Lupus Erythematosus Early Phase 1
Not yet recruiting NCT03899298 - Safety and Clinical Outcomes With Amniotic and Umbilical Cord Tissue Therapy for Numerous Medical Conditions Phase 1
Completed NCT04005456 - Personalized Lifestyle Intervention for Improving Functional Health Outcomes Using N-of-1 Tent-Umbrella-Bucket Design N/A
Recruiting NCT05085444 - A Study of CD19/BCMA Chimeric Antigen Receptor T Cells Therapy for Patients With Refractory Scleroderma Early Phase 1
Recruiting NCT05853835 - First-in-Human Trial in Healthy Adult Volunteers to Evaluate Safety, Tolerability and PK of LAPIX Study Drug; LPX-TI641 Phase 1